Colorectal Cancer Dataset in Xijing Hospital From 2011

Chemotherapy Clinical Trial

Official title:

Colorectal Cancer Dataset in Xijing Hospital From 2011

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06308354
• Other study ID #: CRC dataset
• Status: Recruiting
• Start date: January 1, 2011
• Est. completion date: January 1, 2048

Study information

• Verified date: January 2024
• Source: Xijing Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40000
• Est. completion date: January 1, 2048
• Est. primary completion date: January 1, 2048
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• 1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;

• 2. Visit our center with complete medical records and pathological information;

• 3. Colorectal cancer patients diagnosed between 2013 and 2023.

Exclusion Criteria:

• 1. The patient has other colorectal malignancies other than adenocarcinoma;

• 2. Malignant tumors adjacent to organs invading the colon and rectum;

• 3. Malignant tumors from distant organs metastasize to the colon and rectum;

• 4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.

Related Conditions & MeSH terms

• Chemotherapy
• Colorectal Neoplasms
• Nutrition Related Cancer

Locations

Country	Name	City	State
China	Fourth Military Medical University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	to dead or lost to follow	from date of diagnosis until the date of death from any cause, assessed up to 120 months
Primary	DFS	disease-free survival	from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months